B7-H3-Targeted Antibody-Drug Conjugates | Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates

Featuring perspectives from Dr Manish Patel, including the following topics: Insights into a comprehensive clinical research practice (0:00) Transformation of the conduct and design of clinical trials (3:41) Disparities and conundrums in clinical trial recruitment (10:11) Rationale of clinical trial dosing and regulatory initiatives (15:37) Innovation and advancements in oncology research and clinical development (18:47) Practical considerations into patient care during a clinical trial (20:52) Encouraging physicians to participate in oncology research (24:29) Pharmacology of B7-H3 and role in tumor pathogenesis (31:56) Current and future clinical development of ifinatamab deruxtecan (I-DXd) (34:11) Available clinical data with vobramitamab duocarmazine across numerous solid tumors (1:02:44) Early clinical data with HS-20093 for advanced solid tumors (1:06:36) CME information and select publications